BC Innovations | Apr 10, 2018
Distillery Techniques


TECHNOLOGY: Biosynthesis A liver microsome-based biosynthesis method could be used to generate multiple analogs of drug compounds. The method involves four steps: generating preparations of liver microsomes from eight mammalian species (mouse, rat, hamster, guinea...
BC Innovations | Apr 4, 2017
Distillery Techniques


TECHNOLOGY: Tool compounds A triazolopyrimidine-based PDE-2 inhibitor could help probe the protein's role in cognitive dysfunction. High throughput screening of a small molecule library in an in vitro activity assay and subsequent structural optimization and...
BC Week In Review | Mar 5, 2012
Company News

biocrea, Boehringer Ingelheim deal

Boehringer acquired biocrea's phosphodiesterase-2 (PDE-2) program. The program's lead compound is BCA909 , a PDE-2 inhibitor in preclinical testing for mild cognitive impairment and Alzheimer's disease (AD). biocrea will receive an undisclosed cash payment from Boehringer....
BC Week In Review | Sep 19, 2011
Clinical News

biocrea preclinical data

In rats, BCR909 significantly reversed impaired novel object recognition that resulted from either disruption of cholinergic or glutamatergic neurotransmission. Furthermore, the phosphodiesterase-2 (PDE-2) inhibitor did not induce tolerance. Data were presented at the European College...
BC Innovations | Apr 29, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma; multiple myeloma (MM) Adenosine A2A receptor (ADORA2A); phosphodiesterase-2 (PDE-2); PDE-3; PDE-4; PDE-7 In vitro studies suggest that ADORA2A agonists and PDE...
BC Week In Review | Oct 16, 2006
Company News

Neuro3d neurology news

Neuro3d said it is winding down its operations and has terminated development of its ND1251 and ND7001. The compounds, which inhibit phosphodiesterase-4 (PDE-4) and PDE-2, respectively, showed toxicity in early testing. ND1251 was in Phase...
BC Extra | Oct 11, 2006
Company News

Neuro3d ending operations

CNS company Neuro3d (Mulhouse, France) is winding down its operations after phosphodiesterase-4 (PDE-4) inhibitor ND1251 for depression exhibited toxicity in Phase I testing and PDE-2 inhibitor ND7001 showed preclinical toxicity. Development of both products has...
Items per page:
1 - 7 of 7